Analysis of serum VPF family expression profile and Hcy level in early pregnancy and their predictive value for pregnancy outcomes in pregnant women with preeclampsia
10.3760/cma.j.cn431274-20250117-00074
- VernacularTitle:孕早期血清VPF家族表达谱及Hcy水平对子痫前期孕妇妊娠结局的预测分析
- Author:
Minxin SHI
1
Author Information
1. 沧州市人民医院产科，沧州 061000
- Publication Type:Journal Article
- Keywords:
Pre-eclampsia;
Vascular endothelial growth factor;
Placenta growth factor;
Homocysteine
- From:
Journal of Chinese Physician
2025;27(9):1382-1387
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression profiles of the vascular permeability factor (VPF) family and homocysteine (Hcy) levels in early pregnancy and their predictive value for pregnancy outcomes in women with preeclampsia.Methods:Clinical data from 168 pregnant women with preeclampsia who were treated at the Cangzhou People′s Hospital between February 2022 and February 2024 were collected, including 114 with non-severe preeclampsia and 54 with severe preeclampsia. Additionally, 100 healthy pregnant women with matched clinical data were included as controls. Differences in serum levels of vascular endothelial growth factor (VEGF)-A, VEGF-B, placental growth factor (PLGF), and Hcy were compared between the control group and the preeclampsia group, as well as among subgroups of preeclampsia with different severity levels and pregnancy outcomes. Logistic regression analysis was used to evaluate factors influencing adverse pregnancy outcomes in women with preeclampsia. Receiver operating characteristic (ROC) curves were plotted, and the area under the curve (AUC) was calculated to assess the predictive performance of each factor for adverse pregnancy outcomes.Results:Serum levels of VEGF-A and PLGF in the preeclampsia group during early pregnancy were (95.45±10.65)pg/ml and (105.49±16.63)pg/ml, respectively, significantly lower than those in the control group. Hcy levels were (24.50±5.74)μmol/L, significantly higher than those in the control group (all P<0.05). In the severe preeclampsia subgroup, VEGF-A and PLGF levels were (89.83±9.05)pg/ml and (94.61±15.98)pg/ml, significantly lower than those in the non-severe subgroup. Hcy levels were (26.86±5.92)μmol/L, significantly higher than those in the non-severe subgroup (all P<0.05). Among women with adverse pregnancy outcomes, VEGF-A and PLGF levels were (87.29±7.55)pg/ml and (89.43±12.80)pg/ml, significantly lower than those in women with normal outcomes. Hcy levels were (28.60±5.76)μmol/L, significantly higher than those in women with normal outcomes (all P<0.05). Multivariate logistic regression analysis indicated that VEGF-A and PLGF were protective factors against adverse pregnancy outcomes, while Hcy was a risk factor (all P<0.05). ROC analysis showed that the AUC values for VEGF-A, PLGF, Hcy alone, and their combination in predicting adverse pregnancy outcomes were 0.827, 0.895, 0.778, and 0.965, respectively (all P<0.05). Conclusions:Changes in serum levels of VEGF-A, PLGF, and Hcy in early pregnancy are associated with the risk of preeclampsia. Combined detection of these markers in early pregnancy has high predictive value for pregnancy outcomes in women with preeclampsia.
